CXCR4 antagonism corrects neutrophil abnormalities and reduces pneumonia severity in a pharmacological mouse model of CXCR2 loss-of-function-mediated neutropenia. This evidence concerns the gene CXCR2 and susceptibility to pneumonia measurement.